Trends in Cardiovascular Medicine
Volume 18, Issue 2 , Pages 61-66, February 2008

The Effect of Apolipoprotein Mimetic Peptides in Inflammatory Disorders Other Than Atherosclerosis

  • Mohamad Navab

      Affiliations

    • Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, USA
    • Corresponding Author InformationAddress correspondence to: Mohamad Navab, Room BH-307 CHS, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 10833, Le Conte Avenue, Los Angeles, CA 90095-1679, USA. Tel.: (+1) 310 206 2678; fax: (+1) 310 206 9133
    • ,
  • G.M. Anantharamaiah

      Affiliations

    • Department of Medicine, Atherosclerosis Research Unit, University of Alabama, Birmingham, Birmingham, AL 35294-0012, USA
    • ,
  • Alan M. Fogelman

      Affiliations

    • Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, USA

Received 15 October 2007; received in revised form 14 December 2007; accepted 19 December 2007.

Apolipoprotein mimetic peptides have been shown to dramatically reduce atherosclerosis in animal models. Atherosclerosis is an example of an inflammatory disorder. Published studies of apolipoprotein mimetic peptides in models of inflammatory disorders other than atherosclerosis suggest that they may have efficacy in a wide range of inflammatory conditions.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 M. Navab, G. M. Anantharamaiah, and A. M. Fogelman are principals in Bruin Pharma (Los Angeles, CA).

PII: S1050-1738(08)00002-9

doi:10.1016/j.tcm.2007.12.006

Trends in Cardiovascular Medicine
Volume 18, Issue 2 , Pages 61-66, February 2008

Article Tools

* Image Usage & Resolution